arrow_back Back to App

Increased Transparency for Pharmaceutical Research Costs

New legislation increases public access to information about the costs of drug clinical trials and pharmaceutical companies' development spending. This aims to help citizens better understand drug prices by making data on development costs available.
Key points
Companies conducting drug clinical trials must post detailed cost data for these trials on a public website.
Publicly traded drug manufacturers must disclose their annual drug research and development expenditures in financial reports, broken down by development stage.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_7474
Sponsor: Rep. Maloney, Carolyn B. [D-NY-12]
Process start date: 2022-04-07
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-04-17
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Pharmaceutical Research Transparency Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_7474.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-04-07.

What are the main provisions?

Key points include:

  • Companies conducting drug clinical trials must post detailed cost data for these trials on a public website.
  • Publicly traded drug manufacturers must disclose their annual drug research and development expenditures in financial reports, broken down by development stage.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Maloney, Carolyn B. [D-NY-12].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Economy